<DOC>
	<DOCNO>NCT02532283</DOCNO>
	<brief_summary>The purpose study evaluate Pharmacokinetic parameter JNJ-63623872 combination oseltamivir elderly participant ( age 65 &lt; = 85 year ) compare adult ( age 18 &lt; = 64 year ) influenza A infection .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics , Safety , Antiviral Activity JNJ-63623872 Combination With Oseltamivir Adult , Elderly Hospitalized Participants With Influenza A Infection</brief_title>
	<detailed_description>This randomize ( study medication assign participant chance ) , double-blind ( neither researcher participant know treatment participant receiving ) , placebo-controlled , multicenter ( one hospital medical school team work medical research study ) study evaluate effect JNJ-63623872 combination oseltamivir participant influenza A infection . The study consist 3 Phases : Screening visit ( 1 Day ) , participant meet eligibility criterion randomize 2:1 ratio receive study drug double-blind treatment Phase ( 7 Days ) follow Phase ( 21 Days ) . The duration participation study participant approximately 28 Days . Primarily Pharmacokinetic parameter JNJ-63623872 measure . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Participant require hospitalization treat influenza infection and/or treat complication influenza infection Participant test positive influenza A infection within 1 day signing inform consent form ( ICF ) /assent form use polymerase chain reaction ( PCR ) base rapid molecular diagnostic assay Participants must capable swallow study medication tablet capsule Each participant ( legally acceptable representative ) must sign ICF indicate understands purpose procedure require study willing participate study Participant must willing able adhere prohibition restriction specify protocol Participant receive 3 dos influenza antiviral medication oseltamivir , zanamivir , peramivir since start influenza symptom , ribavirin within 6 month prior Screening Participant unwilling undergo regular nasal Midturbinate ( MT ) swab physical abnormality limit ability collect regular nasal specimen Participant immunocompromised , whether due underlie medical condition ( example , malignancy ) medical therapy ( example , medication , chemotherapy , radiation , posttransplant ) Participant undergo peritoneal dialysis , hemodialysis , hemofiltration Participant estimate glomerular filtration rate ( eGFR ) less equal ( &lt; = ) 30 milliliter ( mL ) /minute ( min ) /1.73 meter^2 ( m^2 ) accord Modification Diet Renal Disease ( MDRD ) equation , assess Screening base recent clinically relevant creatinine value available</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Influenza A virus</keyword>
	<keyword>JNJ-63623872</keyword>
	<keyword>Oseltamivir</keyword>
</DOC>